Early Phase 2 data with high-dose aflibercept promising in wet AMD
August 24, 2021
Regeneron Pharmaceuticals announced at an ongoing Phase 2 trial has met its primary safety endpoint with no new safety signals observed.
© 2021 MJH Life Sciences™ and Ophthalmology Times. All rights reserved.
AMD Awareness
Companies announce eye care collaboration
September 13, 2021
AbbVie and REGENXBIO announced a strategic partnership to develop and commercialize RGX-314, an investigational gene therapy for wet age-related macular degeneration, diabetic retinopathy and other chronic retinal diseases.
Wet AMD: Current therapies and treatment
May 18, 2021
Experts discuss durability of action and atrophy inhibitor among primary treatment goals.
Unmet Needs and the Future of Wet AMD Care
March 23, 2021
Expert panelists provide an overview of current unmet needs in wet AMD care and discuss the potential for improving clinical outcomes and treatment burden.
Clinical Trials of Alternative Targets in Wet AMD
March 23, 2021
Key opinion leaders in ophthalmology comment on the potential role of alternative targets beyond VEGF-A including VEGF-C/VEGF-D and tyrosine kinase inhibitors.
Emerging Treatments for Wet AMD
March 23, 2021
A panel of expert ophthalmologists provides insight into emerging clinical trial data on new molecules, surgical implants, and gene therapy in wet AMD.
Diagnostic Imaging of Nonexudative Neovascular AMD
March 23, 2021
A panel of experts discusses nonexudative neovascular AMD and challenges associated with diagnostic imaging such as OCT-A and fluorescein angiography.
Factors to Consider When Selecting Therapy in Wet AMD
March 23, 2021
Key opinion leaders discuss factors to consider when selecting treatments in wet AMD including insurance considerations and degree of clinical response.
Theoretical Systemic Safety of Anti-VEGF in Wet AMD
March 23, 2021
Panelists consider the theoretical systemic safety of anti-VEGF agents in wet AMD and discuss their role in the management of patients with risk factors.
Safety and Efficacy of Available Treatments in Wet AMD
March 23, 2021
Experts compare the safety and efficacy of agents currently available for wet AMD treatment and emphasize the importance of post-marketing surveillance.